Pipeline Close Domain Therapeutics presents most recent developments of its BRET technology portfolio at AACR and ASPET event Presented posters highlight novel BRET-based assays to characterize RTK and ICP targets and reveal extensive profiling of signaling signature of 100 GPCRs Strasbourg, France, April 08, 2021 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology and rare diseases, today announces the presentation of the latest developments in its proprietary BRET-based1 technology bioSens-All™️ and an extensive and unique profiling of GPCR signaling signatures, at the American Association for Cancer Research (AACR) and the American Society for Pharmacology and Experimental Therapeutics (ASPET) virtual meetings, in April 2021. The three posters disclose: Innovative BRET assays to profile Tyrosine Kinase Receptor Inhibitors (TKIs) as a new dimension to select differentiated therapeutic candidates BRET-based biosensors to characterize immune checkpoint inhibitors (ICIs) bringing new pharmacology insights for immuno-oncology The profiling of signaling pathways of 100 GPCRs, to unveil pharmacology complexity “We are very proud to share the latest developments in our bioSens-All™️ technology. They illustrate how powerful this platform is and the added-value it brings to help identify and characterize GPCR targeting drug candidates,” said Dr Xavier Leroy, Chief Technology Officer at Domain Therapeutics. “This technology brings differentiated and novel insights not only on GPCRs, but also on other membrane receptors such as receptor tyrosine kinases (RTKs) and immune checkpoints (ICPs).” Disclosing the company’s most recent developments, the poster ‘EGFR signaling and pharmacology in oncology revealed with an innovative RTK biosensor technology’ (AACR, April 10-15, Poster #LB187), presents a powerful tool and case studies for the analysis of RTK mutations and for the identification of a new generation of TKIs and antibodies directed against RTKs. The poster ‘A high value pharmacological platform dedicated to the real-time study of stimulatory immune checkpoint signaling pathways’ (AACR, April 10-15, Poster #LB123) illustrates several innovative BRET assays developed by Domain Therapeutics and dedicated to both inhibitory and stimulatory ICPs (PD-1, CTLA-4, 4-1BB) with small molecules or antibodies. Such spatio-temporal cell-based functional assays can support broad drug programs, including high-throughput functional screening, lead optimization and bioanalytical quality control lot release. The poster ‘Use of Novel ebBRET Biosensors for Comprehensive Signaling Profiling of One Hundred Therapeutically Relevant Human GPCRs’ (ASPET, April 27-30, Poster #R1694) describes a novel suite of proprietary enhanced bystander BRET biosensors used to profile the signaling repertoire of 100 therapeutically relevant human unmodified GPCRs. Together, the resources provided in this study help deconvolute the complexities of GPCR biology and pharmacology, and lead to innovative therapeutic exploitation of GPCRs. The posters and audio description can be downloaded from the AACR and ASPET websites (weblinks in poster titles above) and here on Domain Therapeutics website. 1 Bioluminescence Resonance Energy Transfer Pipeline Partnering Opportunities Resources Careers Contact us 77/100 2021 #Discovermorethanyouthink Strasbourg - Illkirch Domain Therapeutics SA Bioparc 1 - 850 Boulevard Sébastien Brant 67400 Strasbourg - Illkirch - France https://www.domaintherapeutics.com/ Montreal Domain Therapeutics NA Inc. Neomed Institute - 7171 Frédérick Banting H4S 1Z9 Montreal - Canada https://www.domaintherapeutics.ca/ © 2021 Domain Therapeutics - All rights reserved Privacy Legal notices RSS Axeptio consent